Curriculum Vitae
Jean-Christophe Corvol, Born in 1971, August 5th, French, marital life
Address: CIC Neuro, bâtiment ICM, Hôpital Pitié-Salpêtrière, 47/83 Bd de l’Hôpital, 75013 Paris, France
Tel: +33 1 42 16 57 66. Fax: +33 1 42 16 57 67,
Neurologist, Pharmacologist, CNOM #: 75/69402, ADELI#: 751694027, RPPS#: 10001556389
Current position
2010 - Associate coordinator of the French CIC Neurosciences Network (NS-Park)
2008 - Coordinator of the Clinical Neurosciences Research Center (CIC-9503), Pitié-Salpêtrière Hospital
2008 - PI, team 1 (Pr Brice), CR-ICM, UPMC, INSERM UMRS-975, CNRS UMR7225, Pitié-Salpêtrière Hospital
2007 - Assistant Professor (MCU-PH), Department of Pharmacology, Pitié-Salpêtrière Hospital
Education
2009 Research Habilitation, University Paris VI (UPMC)
2005 PhD, University Paris VI (UPMC)
2003 MD, Neurology, University Paris VI (UPMC)
2000 Master in molecular and cellular pharmacology, University Paris VI (UPMC)
Past positions and training
2006-2007 Post-doctoral position, Molecular Neurogenetic Laboratory, UCSF, San Francisco, USA
2005-2006 Clinical Assistant, Department of Pharmacology, Pitié-Salpêtrière hospital
2003-2005 Clinical Assistant, Department of Neurology, Pitié-Salpêtrière hospital
2001-2003 PhD training, INSERM U536, JA Girault, Institut du fer à moulin, Paris.
1999-2000 Master training, INSERM U114, J. Glowinski, Collège de France, Paris.
1995-2001 Residency in Neurology, Paris
Clinical research
GCP
Web-based training course “Protecting Human Research Participants” (NIH). 2011
Coordination of clinical research studies:
- Predictive factor of DBS response in PD (PREDISTIM). Physiopathology, multicenter, national. APHP. PI. 2013-2016.
- Amantadine and L-dopa induced dyskinesia. Phase II, multicenter, national. CHU Toulouse. NCT01538329. PI for site. 2012-15
- AQW051 in L-dopa Induced Dyskinesia. Phase II, multicenter, international. Novartis. NCT01474421. PI for site. 2012-2013
- Behavioral Addiction and Genes in PD (BADGE-PD). Physiopathology, multicenter, national. APHP. PI. 2011-2013.
- Drug Interaction with Genes in PD (DIGPD). Physiopathology, multicenter, national. APHP. NCT01564992. PI. 2009-2014.
- ADX48621 in L-dopa Induced Dyskinesia. Phase II, multicenter, international. Addex. NCT01336088. PI for site. 2011-2012
- Davunetidein PSP. Phase II, multicenter, international. Allon Therapeutics. NCT01110720. PI for France. 2011-2012
- Blood brain barrier in Parkinson Plus Syndroms. Physiopathology, multicenter, national. APHP. PI for site. 2006-2012
- IPX066 In Advanced PD. Phase III, multicenter, international. IMPAX. NCT00974974. . PI for France. 2009-2010
- COMT polymorphism and entacapone efficacy in PD. Phase IV, monocenter. NCT00373087. APHP. PI. 2007-2009
- Heart valve disease and pergolide in PD. Phase IV, monocenter. SFC. NCT00202657. PI. 2006-2007
Co-Investigator in more than 20 clinical trials and clinical research studies. (since 2003)
Member of scientific societies and boards
- Commission Scientifique Spécialisée n°6: Neurosciences, Cognition, Santé Mentale (CSS6, INSERM, 2012-)
- Scientific board of the French Parkinson association (2010-)
- Scientific board of the Fédération pour la Recherche sur le Cerveau (FRC) (2010-)
- French Society of Pharmacology (2003-)
- French Society of Neurology (2003-)
- Comité d'orientation stratégique et de suivi des essais cliniques (Cossec, INSERM, 2009-2012)
- Scientific Board of the French College of Pharmacology (2008-2012)
- Advisory board of the European College of Neuropsychopharmacology (2005-2012)
Awards
2011 Prix Association pour le Développement de la Pharmacologie Clinique/Patrice Jaillon
2006 Prix jeune chercheur, Fondation Bettencourt-Schüller
Date : 01 January 2013
Signature :
Publications (by publication date)
Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D; Parkgait-II study group. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012 Jul;11(7):589-96.
Depienne C, Bouteiller D, Méneret A, Billot S, Groppa S, Klebe S, Charbonnier-Beaupel F, Corvol JC, Saraiva JP, Brueggemann N, Bhatia K, Cincotta M, Brochard V, Flamand-Roze C, Carpentier W, Meunier S, Marie Y, Gaussen M, Stevanin G, Wehrle R, Vidailhet M, Klein C, Dusart I, Brice A, Roze E. RAD51 haploinsufficiency causes congenital mirror movements in humans. Am J Hum Genet. 2012 Feb 10;90(2):301-7.
Keller MF, Saad M, Bras J, Bettella F, Nicolaou N, Simón-Sánchez J, Mittag F, Büchel F, Sharma M, Gibbs JR, Schulte C, Moskvina V, Durr A, Holmans P, KilarskiLL, Guerreiro R, Hernandez DG, Brice A, Ylikotila P, Stefánsson H, Majamaa K, Morris HR, Williams N, Gasser T, Heutink P, Wood NW, Hardy J, Martinez M, Singleton AB, Nalls MA; International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2)*. Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet. 2012 Nov 15;21(22):4996-5009.
Holmans P, Moskvina V, Jones L, Sharma M; The International Parkinson's Disease Genomics Consortium (IPDGC), Vedernikov A, Buchel F, Sadd M, Bras JM, Bettella F, Nicolaou N, Simón-Sánchez J, Mittag F, Gibbs JR, Schulte C, Durr A, Guerreiro R, Hernandez D, Brice A, Stefánsson H, Majamaa K, Gasser T, Heutink P, Wood NW, Martinez M, Singleton AB, Nalls MA, Hardy J, Morris HR, Williams NM.* A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet. 2012 Dec 13. [Epub ahead of print]
Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van Broeckhoven C, Bertram L, Bozi M, Crosiers D, Clarke C, Facheris M, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon B, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEO-PD Consortium*. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012 Aug 14;79(7):659-67. *Corvol JC, among 103 collaborators.
Lesage S, Condroyer C, Klebe S, Honoré A, Tison F, Brefel-Courbon C, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group*. Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology. 2012 May 1;78(18):1449-50. *Corvol JC, among 23 collaborators.
Metso TM, Tatlisumak T, Debette S, Dallongeville J, Engelter ST, Lyrer PA, Thijs V, Bersano A, Abboud S, Leys D, Grond-Ginsbach C, Kloss M, Touzé E, Pezzini A, Metso AJ; CADISP group*. Migraine in cervical artery dissection and ischemic stroke patients. Neurology. 2012 Apr 17;78(16):1221-8. *Corvol JC, among 14 collaborators.
Rosso C, Corvol JC, Pires C, Crozier S, Attal Y, Jacqueminet S, Deltour S, Multlu G, Leger A, Meresse I, Payan C, Dormont D, Samson Y. Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke. 2012 Sep;43(9):2343-9.
Lesage S, Condroyer C, Klebe S, Lohmann E, Durif F, Damier P, Tison F, Anheim M, Honoré A, Viallet F, Bonnet AM, Ouvrard-Hernandez AM, Vidailhet M, Durr A, Brice A; French Parkinson's Disease Genetics Study Group*. EIF4G1 in familial Parkinson's disease: pathogenic mutations or rare benign variants? Neurobiol Aging. 2012 Sep;33(9):2233.e1-2233.e5. *Corvol JC, among 23 collaborators.
Metso AJ, Metso TM, Debette S, Dallongeville J, Lyrer PA, Pezzini A, Lichy C, Kloss M, Brandt T, Touzé E, Southerland AM, Worrall BB, Abboud S, del Zotto E, Leys D, Engelter S, Grond-Ginsbach C, Tatlisumak T; CADISP Group*. Gender and cervical artery dissection. Eur J Neurol. 2012 Apr;19(4):594-602. *Corvol JC, among 14 collaborators.
Engelter ST, Dallongeville J, Kloss M, Metso TM, Leys D, Brandt T, Samson Y, Caso V, Pezzini A, Sessa M, Beretta S, Debette S, Grond-Ginsbach C, Metso AJ, Thijs V, Lamy C, Medeiros E, Martin JJ, Bersano A, Tatlisumak T, Touzé E, Lyrer PA; Cervical Artery Dissection and Ischaemic Stroke Patients-Study Group*. Thrombolysis in cervical artery dissection--data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database. Eur J Neurol. 2012 Sep;19(9):1199-206. *Corvol JC, among 78 collaborators.
Pradat PF, Dubourg O, de Tapia M, di Scala F, Dupuis L, Lenglet T, Bruneteau G, Salachas F, Lacomblez L, Corvol JC, Demougin P, Primig M, Meininger V, Loeffler JP, Gonzalez de Aguilar JL. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener Dis. 2012;9(1):38-52.
Cormier F, Muellner J, Corvol JC. Genetics of impulse control disorders in Parkinson's disease. J Neural Transm. 2012 Dec 12. [Epub ahead of print]
Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. Fundam Clin Pharmacol. 2012 Aug;26(4):557-64.
Corvol JC. Neuroprevention: A new challenge? Rev Neurol (Paris). 2012 Nov;168(11):796-801.
International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW.* Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011 Feb 19;377(9766):641-9. *Corvol JC, among 126 collaborators.
Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium*. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011 Oct;10(10):898-908. *Corvol JC, among 108 collaborators.
Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol. 2011 Jan;69(1):111-8.
Ros-Bernal F, Hunot S, Herrero MT, Parnadeau S, Corvol JC, Lu L, Alvarez-Fischer D, Carrillo-de Sauvage MA, Saurini F, Coussieu C, Kinugawa K, Prigent A, Höglinger G, Hamon M, Tronche F, Hirsch EC, Vyas S. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6632-7.
International Parkinson's Disease Genomics Consortium (IPDGC); Wellcome Trust Case Control Consortium 2 (WTCCC2)*. A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet. 2011 Jun;7(6):e1002142. *Corvol JC, among 139 collaborators.
Depienne C, Cincotta M, Billot S, Bouteiller D, Groppa S, Brochard V, Flamand C, Hubsch C, Meunier S, Giovannelli F, Klebe S, Corvol JC, Vidailhet M, Brice A, Roze E. A novel DCC mutation and genetic heterogeneity in congenital mirror movements. Neurology. 2011 Jan 18;76(3):260-4.
Lesage S, Condroyer C, Hecham N, Anheim M, Belarbi S, Lohman E, Viallet F, Pollak P, Abada M, Dürr A, Tazir M, Brice A; French Parkinson Disease Genetic Group*. Mutations in the glucocerebrosidase gene confer a risk for Parkinson disease in North Africa. Neurology. 2011 Jan 18;76(3):301-3. *Corvol JC, among 22 collaborators.
Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, Lambert JC, Vidailhet M, Mellick GD, Lohmann E, Durif F, Pollak P, Damier P, Tison F, Silburn PA, Tzourio C, Forlani S, Loriot MA, Giroud M, Helmer C, Portet F, Amouyel P, Lathrop M, Elbaz A, Durr A, Martinez M, Brice A; French Parkinson's Disease Genetics Study Group. Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet. 2011 Feb 1;20(3):615-27.
Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, Viallet F, Lohmann E, Corvol JC, Honoré A, Rivaud S, Vidailhet M, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet. 2011 Jan 1;20(1):202-10.
Vorspan F, Mallet L, Corvol JC, Pelissolo A, Lépine JP. Treating addictions with deep brain stimulation is premature but well-controlled clinical trials should be performed. Addiction. 2011 Aug;106(8):1535-6;
Bonnet AM, Jutras MF, Czernecki V, Corvol JC, Vidailhet M. Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects. Parkinsons Dis. 2012;2012:198316.
Schüpbach WM, Corvol JC, Czernecki V, Djebara MB, Golmard JL, Agid Y, Hartmann A. Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):20-5.
Pineau F, Schüpbach M, Corvol JC, Flamand-Rouvière C, Vidailhet M, Roze E. Long-standing paraphilia induced by dopamine agonists in Parkinson's disease. Mov Disord. 2010 May 15;25(7):963-5.
Dujardin K, Dubois B, Tison F, Durif F, Bourdeix I, Péré JJ, Duhamel A; EXECUTIVE study group*. Parkinson's disease dementia can be easily detected in routine clinical practice. Mov Disord. 2010 Dec 15;25(16):2769-76. *Corvol JC, among 48 collaborators.
Soubrier M, Haïk S, Hauw JJ, Corvol JC, Lyon-Caen O, Dougados M. Creutzfeldt-Jakob disease in a patient treated by etanercept for rheumatoid arthritis (RA): just a coincidence? Joint Bone Spine. 2010 Mar;77(2):174-5.
Devos D; French DUODOPA Study Group*. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord. 2009 May 15;24(7):993-1000. *Corvol JC, among 60 collaborators.
Corvol JC, Pelletier D, Henry RG, Caillier SJ, Wang J, Pappas D, Casazza S, Okuda DT, Hauser SL, Oksenberg JR, Baranzini SE. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11839-44.
Faure C*, Corvol JC*, Toutant M, Valjent E, Hvalby O, Jensen V, El Messari S, Corsi JM, Kadaré G, Girault JA. Calcineurin is essential for depolarization-induced nuclear translocation and tyrosine phosphorylation of PYK2 in neurons. J Cell Sci. 2007 Sep 1;120(Pt 17):3034-44. *co-first authors.